Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382318093> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W4382318093 abstract "Anti-CD19 immunotherapy tafasitamab in combination with lenalidomide is used in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant. Open-label, phase 1b, First-MIND study assessed safety and preliminary efficacy of tafasitamab + R-CHOP ± lenalidomide as first-line therapy in patients with DLBCL. Adults with newly-diagnosed, untreated DLBCL (ECOG PS 0-2, IPI 2-5), were randomly assigned to RCHOP+tafasitamab (Arm T) or R-CHOP+tafasitamab+lenalidomide (Arm T/L) for six cycles. Primary endpoint was safety; secondary endpoints included overall response rate (ORR) and complete response (CR) rate at end of treatment (EoT). From Dec2019-Aug2020, 83 patients were screened, 66 treated (n=33 per arm). All patients had ≥1 treatment-emergent adverse event, mostly grade 1/2. Grade ≥3 neutropenia and thrombocytopenia occurred in 57.6% and 12.1% of patients (Arm T), and 84.8% and 36.4% (Arm T/L). Non-hematologic toxicities occurred at similar rates between arms. Mean relative dose intensity of R-CHOP was 89% or higher in both arms. ORR at EoT was 75.8% (CR 72.7%) in Arm T and 81.8% (CR 66.7%) in Arm T/L; best ORR across visits was 90.0% and 93.9%. Eighteen-month duration of response and duration of CR rates were 72.7% and 74.5% (Arm T), and 78.7% and 86.5% (Arm T/L); 24-month progression-free survival and overall survival rates were 72.7% and 90.3% (Arm T), and 76.8% and 93.8% (Arm T/L). Manageable safety and promising signals of efficacy were observed in both arms. Potential benefit of adding tafasitamab+lenalidomide to R-CHOP is being investigated in phase 3 frontMIND (NCT04824092)." @default.
- W4382318093 created "2023-06-28" @default.
- W4382318093 creator A5016412759 @default.
- W4382318093 creator A5027978059 @default.
- W4382318093 creator A5030896087 @default.
- W4382318093 creator A5036367652 @default.
- W4382318093 creator A5039153062 @default.
- W4382318093 creator A5043574821 @default.
- W4382318093 creator A5045520627 @default.
- W4382318093 creator A5050782079 @default.
- W4382318093 creator A5061107079 @default.
- W4382318093 creator A5061317839 @default.
- W4382318093 creator A5061713890 @default.
- W4382318093 creator A5061916244 @default.
- W4382318093 creator A5064830159 @default.
- W4382318093 creator A5077504536 @default.
- W4382318093 creator A5083154064 @default.
- W4382318093 creator A5088476247 @default.
- W4382318093 date "2023-06-27" @default.
- W4382318093 modified "2023-10-12" @default.
- W4382318093 title "Safety and efficacy of tafasitamab ± lenalidomide added to first-line R‑CHOP for DLBCL: Phase 1b First-MIND study" @default.
- W4382318093 doi "https://doi.org/10.1182/blood.2023020637" @default.
- W4382318093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37369099" @default.
- W4382318093 hasPublicationYear "2023" @default.
- W4382318093 type Work @default.
- W4382318093 citedByCount "0" @default.
- W4382318093 crossrefType "journal-article" @default.
- W4382318093 hasAuthorship W4382318093A5016412759 @default.
- W4382318093 hasAuthorship W4382318093A5027978059 @default.
- W4382318093 hasAuthorship W4382318093A5030896087 @default.
- W4382318093 hasAuthorship W4382318093A5036367652 @default.
- W4382318093 hasAuthorship W4382318093A5039153062 @default.
- W4382318093 hasAuthorship W4382318093A5043574821 @default.
- W4382318093 hasAuthorship W4382318093A5045520627 @default.
- W4382318093 hasAuthorship W4382318093A5050782079 @default.
- W4382318093 hasAuthorship W4382318093A5061107079 @default.
- W4382318093 hasAuthorship W4382318093A5061317839 @default.
- W4382318093 hasAuthorship W4382318093A5061713890 @default.
- W4382318093 hasAuthorship W4382318093A5061916244 @default.
- W4382318093 hasAuthorship W4382318093A5064830159 @default.
- W4382318093 hasAuthorship W4382318093A5077504536 @default.
- W4382318093 hasAuthorship W4382318093A5083154064 @default.
- W4382318093 hasAuthorship W4382318093A5088476247 @default.
- W4382318093 hasBestOaLocation W43823180931 @default.
- W4382318093 hasConcept C126322002 @default.
- W4382318093 hasConcept C141071460 @default.
- W4382318093 hasConcept C143998085 @default.
- W4382318093 hasConcept C203092338 @default.
- W4382318093 hasConcept C2776063141 @default.
- W4382318093 hasConcept C2776364478 @default.
- W4382318093 hasConcept C2776694085 @default.
- W4382318093 hasConcept C2777063308 @default.
- W4382318093 hasConcept C2778559949 @default.
- W4382318093 hasConcept C2778850193 @default.
- W4382318093 hasConcept C2779338263 @default.
- W4382318093 hasConcept C2779725641 @default.
- W4382318093 hasConcept C31760486 @default.
- W4382318093 hasConcept C535046627 @default.
- W4382318093 hasConcept C71924100 @default.
- W4382318093 hasConcept C90924648 @default.
- W4382318093 hasConceptScore W4382318093C126322002 @default.
- W4382318093 hasConceptScore W4382318093C141071460 @default.
- W4382318093 hasConceptScore W4382318093C143998085 @default.
- W4382318093 hasConceptScore W4382318093C203092338 @default.
- W4382318093 hasConceptScore W4382318093C2776063141 @default.
- W4382318093 hasConceptScore W4382318093C2776364478 @default.
- W4382318093 hasConceptScore W4382318093C2776694085 @default.
- W4382318093 hasConceptScore W4382318093C2777063308 @default.
- W4382318093 hasConceptScore W4382318093C2778559949 @default.
- W4382318093 hasConceptScore W4382318093C2778850193 @default.
- W4382318093 hasConceptScore W4382318093C2779338263 @default.
- W4382318093 hasConceptScore W4382318093C2779725641 @default.
- W4382318093 hasConceptScore W4382318093C31760486 @default.
- W4382318093 hasConceptScore W4382318093C535046627 @default.
- W4382318093 hasConceptScore W4382318093C71924100 @default.
- W4382318093 hasConceptScore W4382318093C90924648 @default.
- W4382318093 hasLocation W43823180931 @default.
- W4382318093 hasLocation W43823180932 @default.
- W4382318093 hasOpenAccess W4382318093 @default.
- W4382318093 hasPrimaryLocation W43823180931 @default.
- W4382318093 hasRelatedWork W2111611512 @default.
- W4382318093 hasRelatedWork W2143935650 @default.
- W4382318093 hasRelatedWork W2168450724 @default.
- W4382318093 hasRelatedWork W2584782292 @default.
- W4382318093 hasRelatedWork W2623503649 @default.
- W4382318093 hasRelatedWork W2928264246 @default.
- W4382318093 hasRelatedWork W4283275436 @default.
- W4382318093 hasRelatedWork W4361954667 @default.
- W4382318093 hasRelatedWork W4361966866 @default.
- W4382318093 hasRelatedWork W4382318093 @default.
- W4382318093 isParatext "false" @default.
- W4382318093 isRetracted "false" @default.
- W4382318093 workType "article" @default.